MedTrace Logo

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

NCT00586898 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2016-03-25

Study results available
· View outcomes & findings →

Summary

Objective: To determine the response to rapid hormonal cycling in patients with non-castrate prostate cancer.

Conditions

Interventions

DRUG

GnRH

leuprolide and goserelin are gonadotropin-releasing hormone analogues

DRUG

Ketoconazole

An imidazole antifungal agent. reduces adrenal and testicular androgen production in men

DRUG

Bicalutamide

A pure nonsteroidal antiandrogen

DRUG

Testosterone transdermal gel

an androgenic anabolic steroid

DRUG

Estrogen transdermal patch

Estradiol is the primary and most potent estrogen

Sponsors & Collaborators

Principal Investigators

  • Howard Scher, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00586898 on ClinicalTrials.gov